NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
60 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03040999 2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT02994069 2025-10-14
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Phase 2 Active not recruiting
NCT02586207 2025-10-07
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
Phase 1 Completed
NCT06056310 2025-09-29
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
Phase 1 Terminated
NCT03765918 2025-08-20
MK-3475-689
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00665392 2025-08-01
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00544414 2025-02-19
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02281955 2025-01-07
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02573493 2024-12-27
APA
Washington University School of Medicine
Phase 2 Completed
NCT01530997 2024-11-13
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT02641093 2024-08-29
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT03077243 2024-05-02
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01588431 2024-02-14
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01437449 2024-01-30
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Phase 2 Completed
NCT01711658 2023-10-17
TRYHARD
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT00820248 2023-08-22
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00047008 2023-07-07
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00096174 2023-06-29
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02990468 2023-03-15
BMX-HN
BioMimetix JV, LLC
Phase 1/2 Completed
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT00265941 2022-06-14
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03067610 2022-03-17
INFIELD
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00566540 2021-11-26
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT02759575 2021-03-12
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
University of Cincinnati
Phase 1/2 Completed
NCT00833261 2020-08-21
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00851877 2020-08-21
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02325401 2020-06-11
Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 1 Completed
NCT01133678 2020-05-08
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
Phase 2 Terminated
NCT00721513 2020-04-07
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00468169 2019-10-09
EPIC
University of Chicago
Phase 2 Completed
NCT00882583 2019-01-09
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT00084318 2018-12-12
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00500760 2018-10-17
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Amgen
Phase 2 Completed
NCT01009346 2018-07-17
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT00052429 2018-01-09
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00352118 2017-12-28
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00798655 2017-10-03
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00423930 2017-08-18
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00304278 2017-07-27
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Southern Illinois University
Phase 2 Completed
NCT00547157 2017-03-15
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed